423 related articles for article (PubMed ID: 33752265)
81. N-glycosylation converts non-glycoproteins into mannose receptor ligands and reveals antigen-specific T cell responses in vivo.
Kreer C; Kuepper JM; Zehner M; Quast T; Kolanus W; Schumak B; Burgdorf S
Oncotarget; 2017 Jan; 8(4):6857-6872. PubMed ID: 28036287
[TBL] [Abstract][Full Text] [Related]
82. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
83. Specific glycan elements determine differential binding of individual egg glycoproteins of the human parasite Schistosoma mansoni by host C-type lectin receptors.
Meevissen MH; Driessen NN; Smits HH; Versteegh R; van Vliet SJ; van Kooyk Y; Schramm G; Deelder AM; Haas H; Yazdanbakhsh M; Hokke CH
Int J Parasitol; 2012; 42(3):269-77. PubMed ID: 22673410
[TBL] [Abstract][Full Text] [Related]
84. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
Front Immunol; 2018; 9():2359. PubMed ID: 30369931
[TBL] [Abstract][Full Text] [Related]
85. Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes.
Li H; Xu CF; Blais S; Wan Q; Zhang HT; Landry SJ; Hioe CE
J Immunol; 2009 May; 182(10):6369-78. PubMed ID: 19414790
[TBL] [Abstract][Full Text] [Related]
86. Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
Olvera A; Cedeño S; Llano A; Mothe B; Sanchez J; Arsequell G; Brander C
Front Immunol; 2020; 11():573928. PubMed ID: 33552045
[TBL] [Abstract][Full Text] [Related]
87. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
88. Sweet Immune Checkpoint Targets to Enhance T Cell Therapy.
Derosiers N; Aguilar W; DeGaramo DA; Posey AD
J Immunol; 2022 Jan; 208(2):278-285. PubMed ID: 35017217
[TBL] [Abstract][Full Text] [Related]
89. Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses.
Alam MM; Jarvis CM; Hincapie R; McKay CS; Schimer J; Sanhueza CA; Xu K; Diehl RC; Finn MG; Kiessling LL
ACS Nano; 2021 Jan; 15(1):309-321. PubMed ID: 32790346
[TBL] [Abstract][Full Text] [Related]
90. Glycans as a key factor in self and nonself discrimination: impact on the breach of immune tolerance.
Alves I; Fernandes Â; Santos-Pereira B; Azevedo CM; Pinho SS
FEBS Lett; 2022 Jun; 596(12):1485-1502. PubMed ID: 35383918
[TBL] [Abstract][Full Text] [Related]
91. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
92. The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins.
Zhou Q; Qiu H
J Pharm Sci; 2019 Apr; 108(4):1366-1377. PubMed ID: 30471292
[TBL] [Abstract][Full Text] [Related]
93. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools.
Ito H; Kuno A; Sawaki H; Sogabe M; Ozaki H; Tanaka Y; Mizokami M; Shoda J; Angata T; Sato T; Hirabayashi J; Ikehara Y; Narimatsu H
J Proteome Res; 2009 Mar; 8(3):1358-67. PubMed ID: 19178301
[TBL] [Abstract][Full Text] [Related]
94. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.
Thurin M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):89-100. PubMed ID: 34161162
[TBL] [Abstract][Full Text] [Related]
95. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
96. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
97. Recent advances in photoaffinity labeling strategies to capture Glycan-Protein interactions.
Babulic JL; De León González FV; Capicciotti CJ
Curr Opin Chem Biol; 2024 Jun; 80():102456. PubMed ID: 38705088
[TBL] [Abstract][Full Text] [Related]
98. On antigen-specific signals, immune class regulation and energetics: Report III from the workshops on foundational concepts of immune regulation.
Anderson CC; Bonney EA; Mueller TF; Corthay A; Havele C; Singh NJ; Øynebråten I; Bretscher PA
Scand J Immunol; 2023 Sep; 98(3):e13311. PubMed ID: 38112131
[TBL] [Abstract][Full Text] [Related]
99. Illuminating T cell-dendritic cell interactions in vivo by FlAsHing antigens.
Akkaya M; Al Souz J; Williams D; Kamdar R; Kamenyeva O; Kabat J; Shevach E; Akkaya B
Elife; 2024 Jan; 12():. PubMed ID: 38236633
[TBL] [Abstract][Full Text] [Related]
100. Assessment of Immunologically Potent Carbohydrates.
Wang D
Methods Mol Biol; 2023; 2612():129-139. PubMed ID: 36795364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
